University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Lymphoma
Myelodysplastic Syndromes

First Posted Date: 2004-03-05

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00005946

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-02-19

Last Posted Date: 2019-11-05

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00030602

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-01-01

Last Posted Date: 2019-11-07

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00014183

Locations: 🇺🇸
Veterans Affairs Medical Center - Baltimore, Baltimore, Maryland, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Risperdal

First Posted Date: 2003-03-17

Last Posted Date: 2019-10-01

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 65

Registration Number: NCT00056498

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bryostatin 1
Drug: paclitaxel

First Posted Date: 2003-03-07

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 46

Registration Number: NCT00005028

Locations: 🇺🇸
Wellspan Health - York Cancer Center, York, Pennsylvania, United States
🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

and more 1 locations

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00049374

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00015951

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 22

Registration Number: NCT00003727

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Phase 1

Completed

Conditions: Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Bladder Cancer
Breast Cancer
Colorectal Cancer

Interventions: Biological: LMB-9 immunotoxin

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 25

Registration Number: NCT00005858

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Infection

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00046852

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy